Protara Therapeutics, Inc. (TARA) Stock

Protara Therapeutics, Inc. (TARA) is a Healthcare stock trading at $3.85 (as of 2026-08-21), with a market capitalization of $216.11M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing investigational therapies for cancer and rare diseases. Its lead program includes TARA-002, a cell therapy for lymphatic malformations, and it is also developing intravenous choline chloride for intestinal failure–associated liver disease.

Understand Protara Therapeutics, Inc.: how it makes money

Protara Therapeutics is a clinical-stage biopharmaceutical company developing cancer and rare-disease therapies, including TARA-002 (an investigational cell therapy for lymphatic malformations) and intravenous choline chloride (an investigational phospholipid substrate replacement therapy for intestinal failure associated liver disease), and the provided data does not specify its current revenue sources.

The company is still in clinical development, so its economics in this dataset show no reported product revenue, making value and future profitability depend on clinical outcomes and advancement of its investigational programs.

Business quality (Weak): The provided facts include detailed clinical-response metrics and adverse-event rates, but do not include segment revenue, commercialization data, or a described current revenue model. Financials shown for the latest period indicate no reported revenue.

Bull case

Complete Response Rate is reported at 70.0% (Any Time): The company reports a Complete Response Rate at any time of 70.0%.
High-grade complete responses are reported at 72.4% (Any Time): The company reports a High-Grade Complete Response Rate (Any Time) of 72.4%.
Durability through the three to six month window is reported as 100.0% for maintained complete response: For the metric 'Patients Maintaining Complete Response from Three to Six Months,' the value reported is 100.0%.

Bear case

Reported operating margin is deeply negative in the latest period shown: For 2026-03-31, operating margin is -1062.8 and revenue is 0.0B in the provided data.
Treatment-related adverse events are reported at 26.0% (Any Grade): The metric 'Treatment-Related Adverse Events at Any Grade' is 26.0%.
Complete response durability declines by 12 months in the reported cohorts: The metric 'Complete Response Rate at Twelve Months (Bacillus Calmette-Guerin Unresponsive Cohort)' is 33.3%, and 'Complete Response Rate at Twelve Months (Bacillus Calmette-Guerin Naive Cohort)' is 57.9%.

Valuation — source: SEC EDGAR (first-party)
Price	$3.85
Market Cap	$216.11M
Price / Book	1.34
Price / Sales	31.54
FCF Yield	-35.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.38M
Net Margin	-900.3%
Revenue Growth (YoY)	53.0%
EPS Growth (YoY)	-38.2%
FCF Growth (YoY)	57.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	7.40 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($27.15M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jesse Shefferman
Employees	28
Country	US
IPO Date	2014-10-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.